Overview

Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas

Status:
Active, not recruiting

Trial end date:
2022-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this research study is to test if Axitinib together with Pembrolizumab can slow tumor growth and know the side effects of the combination treatment.

Phase:

Phase 2

Details

Lead Sponsor:

Breelyn Wilky
Jonathan Trent, MD, PhD

Collaborators:

Merck Sharp & Dohme Corp.
Pfizer

Treatments:

Axitinib
Pembrolizumab